Alveus Therapeutics ApS: Financial statements 2024
CVR: 44689790
Source: annual report 2024, Danish Business Authority
05/03/2024 – 31/12/2024
Alveus Therapeutics ApS (CVR 44689790) has filed annual accounts for 2024. In 2024, the company reported a gross profit of DKK -968,913 and a net result of DKK -5,608,478. Equity in the 2024 report amounted to DKK -5,568,478. The company had 3 employees in the financial year.
- Gross Profit
- DKK -968,913
- Profit/Loss
- DKK -5,608,478
- Equity
- DKK -5,568,478
- Total Assets
- DKK 479,987
- Employees
- 3
Official annual report
Screen every Danish company
Combine filters on financials, industry, geography, property and risk, and instantly see which companies match.
Try company screeningEvents in 2024
As of December 11, 2024, Marie Louise Lindegaard is registered as director of Alveus Therapeutics ApS.
As of December 11, 2024, Lars Peter Brunse has stepped down as director of Alveus Therapeutics ApS.
As of March 5, 2024, Lars Peter Brunse is registered as director of Alveus Therapeutics ApS.
As of March 5, 2024, Nayan Gregory Parekh is registered as adm. dir. of Alveus Therapeutics ApS.
Alveus Therapeutics ApS was founded on March 5, 2024.
About Alveus Therapeutics ApS
Alveus Therapeutics ApS is a Danish company of the type Anpartsselskab based in København K, founded in 2024. The company is registered under the industry Forskning og eksperimentel udvikling inden for naturvidenskab og teknik. The management consists of Rajkumar Kannan. The company's owners include Novo Holdings A/S, Alveus Therapeutics Inc. and FPCI BioDiscovery 7. The company has 12 employees (2026). In 2025, the company reported a gross profit of DKK 22,056,673 and a net result of DKK 2,096,582 compared with DKK -5,608,478 the year before. Equity in the 2025 report amounted to DKK 59,681,194.
